Cole Michael D
Departments of Pharmacology and Genetics, Geisel School of Medicine at Dartmouth College, Lebanon, New Hampshire 03756.
Cold Spring Harb Perspect Med. 2014 Jul 1;4(7):a014316. doi: 10.1101/cshperspect.a014316.
MYC is one of the most frequently mutated and overexpressed genes in human cancer but the regulation of MYC expression and the ability of MYC protein to repress cellular genes (including itself) have remained mysterious. Recent genome-wide association studies show that many genetic polymorphisms associated with disease risk map to distal regulatory elements that regulate the MYC promoter through large chromatin loops. Cancer risk-associated single-nucleotide polymorphisms (SNPs) contain more potent enhancer activity, promoting higher MYC levels and a greater risk of disease. The MYC promoter is also subject to complex regulatory circuits and limits its own expression by a feedback loop. A model for MYC autoregulation is discussed which involves a signaling pathway between the PTEN (phosphatase and tensin homolog) tumor suppressor and repressive histone modifications laid down by the EZH2 methyltransferase.
MYC是人类癌症中最常发生突变和过表达的基因之一,但MYC表达的调控以及MYC蛋白抑制细胞基因(包括其自身)的能力一直成谜。最近的全基因组关联研究表明,许多与疾病风险相关的基因多态性定位于通过大型染色质环调控MYC启动子 的远端调控元件。与癌症风险相关的单核苷酸多态性(SNP)具有更强的增强子活性,可促进更高的MYC水平和更大的疾病风险。MYC启动子也受到复杂调控回路的影响,并通过反馈环限制其自身表达。本文讨论了一种MYC自调控模型,该模型涉及PTEN(磷酸酶和张力蛋白同源物)肿瘤抑制因子与EZH2甲基转移酶产生的抑制性组蛋白修饰之间的信号通路。